Clinical Trial Update: A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating recombinant human vascular endothelial inhibitor in combination with PRaG for advanced refractory non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PRaG (PRaG)
• Recombinant Human Vascular Endothelial Inhibitor (recombinant human vascular endothelial inhibitor)

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Advanced Solid Tumor, Refractory Tumor | Phase 2 | Status: UNKNOWN